Final overall survival (OS) analysis of PROfound: Olaparib vs physician's choice of enzalutamide or abiraterone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations

de Bono, J. S.Mateo, J.Fizazi, K.Saad, F.Shore, N.Sandhu, S.Chi, K. N.Sartor, O.Agarwal, N.Olmos, D.Thiery-Vuillemin, A.Twardowski, P.Roubaud, G.Ozguroglu, M.Kang, J.Burgents, J.Gresty, C.Corcoran, C.Adelman, C. A.Hussain, M.2025-01-072025-01-072020-09-010923-7534https://hdl.handle.net/10668/26987enFinal overall survival (OS) analysis of PROfound: Olaparib vs physician's choice of enzalutamide or abiraterone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterationsconference outputopen access10.1016/j.annonc.2020.08.8701569-8041http://www.annalsofoncology.org/article/S092375342040866X/pdf573469100608